Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Transition to Rebif New Formulation with prophylactic versus PRN ibuprofen in relapsing multiple sclerosis
2006-005972-42Phase 3Completed
- Sponsor
- Merck Serono
- Start
- Apr 2007
- Modality
- Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of interferon beta-1a and ibuprofen in multiple sclerosis (MS) (2 arms), sponsored by Merck Serono. Primary endpoint: Flu-like symptoms score from MSTCQ at week 4. Started Apr 2007; status: completed.
02
Drugs
interferon beta-1aibuprofen
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2006-005972-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005972-42.